DF50 ImpediMed è un dispositivo medico autorizzato dalla FDA. Esso utilizza una singola frequenza di 50 kHz e algoritmi per fornire valutazioni della composizione corporea. A partire da questa data (19 febbraio 2006), DF50 ImpediMed fornisce tre (3) algoritmo che l'utente del dispositivo può scegliere. Tutti e tre sono stati pubblicati in riviste mediche. Qui ci sono le citazioni sui tre algoritmi.
ImpediMed's DF50 is an FDA cleared medical device. It uses a single 50 kHz frequency and algorithms to provide assessments of body composition. As of this date (February 19, 2006), ImpediMed's DF50 provides three (3) algorithm that the user of the device can choose from. All three have been published in peer-reviewed medical journals. Here are the citations on the three algorithms:
General Population - Lukaski, et al
Lukaski HC, Johnson PE, Bolonchuk WW, Lykken GI. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. American Journal of Clinical Nutrition, 41: April 1985, pp 810-817
Obese Population - Segal, et al
Segal K, van Loan M, Fitzgerald PI, Hodgdon J, Van Itallie T. Lean body mass estimation by bioelectrical impedance analysis; a four-site cross-validation study. American Journal of Clinical Nutrition, 47: 1988, pp 7-14
Pediatric Population - Cordain, et al
Cordain L, Whicker R, Johnson J. Body composition determination in children using bioelectrical impedance. Growth Development & Aging, 52:1988 pp 37-40
Un grande riconoscimento di stima per Impediemd
Obama injects local optimism - Olga Galacho - From: Herald Sun - August 10, 2009 12:00AM
LISTED medical device company Impedimed has received a big tick in the US from the Obama administration's push to slash the national healthcare bill through the early detection of illnesses.
The state of North Carolina has ratified legislation requiring health insurance companies to reimburse doctors who regularly test for lymphoedema in breast cancer patients from January 1, 2010.
Impedimed makes the only device approved by the US regulator, the Food and Drug Administration, for early diagnosis of lymphoedema.
The side-effect condition is a painful and disfiguring swelling that occurs in the arms and legs of one in four women after breast cancer surgery.
Impedimed chief executive Greg Brown told BusinessDaily other states were likely to follow North Carolina's example as the new administration consolidated its health reforms.
"I am a bit shocked the Australian market has not picked up on the significance of the US ruling and its implication for Impedimed," Mr Brown said. "We are all set up for meeting the extra demand for the units and expect our annuity stream to kick in around two years time and mature about three years from now."
Premio innovazione tecnologica 2009 vinto da Impedimed Ltd.
ImpediMed Wins 2009 Australian Innovation Shoot Out
Dated: Jan 16, 2009
Silicon Valley Chooses 2009 Australian Innovator of the Year
ImpediMed, representing the State of Queensland, was named winner of the 2009 Australian Innovation Shoot Out following a six-way competition today. Now in its sixth consecutive year, G’DAY USA: Australia Week 2009, which hosts and promotes Australian culture, business, fashion and food, granted each of the six State finalists an opportunity to present their innovation and investment potential to U.S. venture capital investors at the Innovation Shoot Out in Silicon Valley. ImpediMed was selected winner of this year’s competition by a leading panel of judges made up of
Deborah Magid, director of software strategy at IBM Venture Capital Group, Mark Fernandes, managing director of Sierra Ventures, and Harold Yu, partner at Orrick.
ImpediMed’s innovation – the L-Dex – is the only FDA approved medical device capable of aiding medical professionals in detecting secondary lymphedema, a common side effect of modern cancer treatments at an early enough stage to prevent its onset.
Nuovo studio sulla composizione corporea eseguito con l'analizzatore Imp DF-50
Comparison of clinical body composition methods in people taking weight-inducing atypical antipsychotic medications
Asia Pac J Clin Nutr 2008;17 (4):573-579 573
Jenny-Kay Sharpe PhD1,2 , Nuala M Byrne PhD2, Terry J Stedman FRANZCP1, Andrew P Hills PhD2
1The Park – Centre for Mental Health, Treatment, Education, Research, Queensland, Australia 2Institute of Health and Biomedical Innovation, ATN Centre for Metabolic Fitness, Queensland University of Technology, Queensland, Australia.
The purpose of this study was to compare the accuracy of clinical methods to estimate body fat (%BF) in people who take weight-inducing atypical antipsychotic medications. Forty-seven people (35 males, 12 females) with previously diagnosed psychotic illness who had been taking atypical antipsychotic medications for more than 6 months took part in this study. Percentage body fat was estimated using bioelectrical impedance analysis (BIA) and anthropometry from previously published prediction equations and compared with that measured using the deuterium dilution technique which served as the criterion measure. Bland-Altman analyses were used to assess the agreement between measures. In the males, %BF determined using BIA with the Lukaski equation was the only clinical method with mean differences that were not significant from criterion values. While in the females, %BF determined from BMI was the only method that was significantly different from the criterion values. All of the methods of estimating %BF except Watson equations provided consistent estimates across the weight range. Therefore, this study suggests that in a group of people who predominantly had schizophrenia and were taking atypical antipsychotic medications, BIA using the equation of Lukaski was the best indicator of %BF, although on an individual basis the accuracy was poor. BMI underestimated %BF to a greater significant extent than BIA.
The use of BIA rather than BMI may provide a better indicator of adiposity in people who take weight inducing antipsychotic medications.
Bioelectric Impedance Analysis
Body composition was also estimated using an Imp DF50 (Impedimed, Australia) single frequency bioelectrical impedance analyser to determine resistance and reactance at 50 Hz. Standard operating conditions were observed by a trained operator including preparation of the participant, electrode placement and operation of the Imp DF50 bioelectric impedance analyser.28 The measurement using BIA was taken immediately prior to deuterium dosing with participants lying supine, in a rested state. The equations published by Lukaski et al29 and more recently by Sun et al 30 were also used to estimated percentage body fat from the resistance and reactance values recorded by the Imp DF50. The estimate of %BF made using the Lukaski equation is referred to as %BF (LUK) while the estimate of %BF made using the Sun equation is referred to as %BF (SUN).
Nuovo studio sulla composizione corporea nei bambini eseguito con l'analizzatore Imp DF-50
BMC Public Health
Study protocol Open Access
Feasibility, design and conduct of a pragmatic randomized controlled trial to reduce overweight and obesity in children: The electronic games to aid motivation to exercise (eGAME) study Ralph Maddison1, Louise Foley*1, Cliona Ni Mhurchu1, Andrew Jull1, Yannan Jiang1, Harry Prapavessis2, nthony Rodgers3, Stephen Vander Hoorn1, Maea Hohepa4 and David Schaaf5
The ImpediMed DF50 device was used. The yellow and red leads were connected to the electrodes on the participant's wrist and hand respectively, and the blue and black leads were connected to the electrodes on the participant's ankle and foot respectively. During testing, participants were required to lie still and not talk. Two separate readings were taken from each participant. Output values of impedance, phase, resistance and reactance were recorded. FExigaumrpele 1 of child playing Sony EyeToy™ active video game Example of child playing Sony EyeToy™ active video
game. Reproduced with permission from Sony Computer Entertainment Europe. For participants of Ma¯ori or Pacific descent, the Swinburn equation  was used to calculate fat mass, fat free mass and percent body fat.
25 November 2008 - Volume 30 - Issue 22 - p 58
L-Dex U400 Receives FDA Clearance to Aid in Lymphedema Assessment
L-Dex U400, a bioimpedance spectroscopy device, has received clearance by the FDA for use in assisting physicians and other medical professionals in clinical assessment of unilateral lymphedema of the arm in female breast cancer patients. The device is made by ImpediMed.
L-Dex technology uses the characteristics of frequency-dependent current flow to quantify changes in extracellular fluid in patient's limb, a news release from the company notes. These changes can assist in clinical assessment of patients for early signs of lymphedema both preoperatively and
The technology is specific for extracellular fluid, and as fluid differences accumulate, L-Dex values increase on the scale. The device provides an immediate result and is offered with software for tracking changes in the patient's L-Dex value over time. The device is not intended to diagnose or predict lymphedema of an extremity.